Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 1
2005 2
2006 3
2007 3
2009 1
2011 3
2012 1
2013 1
2014 1
2015 2
2016 3
2017 2
2018 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Results by year
Filters applied: . Clear all
Page 1
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Fong PC, et al. Among authors: Swaisland H. N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24. N Engl J Med. 2009. PMID: 19553641 Free article. Clinical Trial.
Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
Swaisland H, Plummer R, So K, Garnett S, Bannister W, Fabre MA, Dota C, Fielding A. Swaisland H, et al. Cancer Chemother Pharmacol. 2016 Oct;78(4):775-84. doi: 10.1007/s00280-016-3124-5. Epub 2016 Aug 23. Cancer Chemother Pharmacol. 2016. PMID: 27553432 Clinical Trial.
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.
Horak J, White J, Harris AL, Verrill M, Carmichael J, Holt A, Cantarini M, Macpherson M, Swaisland A, Swaisland H, Twelves C. Horak J, et al. Among authors: Swaisland A, Swaisland H. Cancer Chemother Pharmacol. 2011 Dec;68(6):1485-95. doi: 10.1007/s00280-011-1611-2. Epub 2011 Apr 13. Cancer Chemother Pharmacol. 2011. PMID: 21487718 Clinical Trial.
Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors.
Rolfo C, Swaisland H, Leunen K, Rutten A, Soetekouw P, Slater S, Verheul HM, Fielding A, So K, Bannister W, Dean E. Rolfo C, et al. Among authors: Swaisland H. Adv Ther. 2015 Jun;32(6):510-22. doi: 10.1007/s12325-015-0214-4. Epub 2015 Jun 6. Adv Ther. 2015. PMID: 26048134 Clinical Trial.
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
Dirix L, Swaisland H, Verheul HM, Rottey S, Leunen K, Jerusalem G, Rolfo C, Nielsen D, Molife LR, Kristeleit R, Vos-Geelen J, Mau-Sørensen M, Soetekouw P, van Herpen C, Fielding A, So K, Bannister W, Plummer R. Dirix L, et al. Among authors: Swaisland H. Clin Ther. 2016 Oct;38(10):2286-2299. doi: 10.1016/j.clinthera.2016.08.010. Epub 2016 Oct 10. Clin Ther. 2016. PMID: 27745744 Clinical Trial.
Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P, Mau-Sørensen M, Nielsen D, Spicer J, Fielding A, So K, Bannister W, Molife LR. Plummer R, et al. Among authors: Swaisland H. Cancer Chemother Pharmacol. 2015 Oct;76(4):723-9. doi: 10.1007/s00280-015-2836-2. Epub 2015 Aug 5. Cancer Chemother Pharmacol. 2015. PMID: 26242220 Clinical Trial.
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery.
Bundred N, Gardovskis J, Jaskiewicz J, Eglitis J, Paramonov V, McCormack P, Swaisland H, Cavallin M, Parry T, Carmichael J, Dixon JM. Bundred N, et al. Among authors: Swaisland H. Invest New Drugs. 2013 Aug;31(4):949-58. doi: 10.1007/s10637-012-9922-7. Epub 2013 Jan 13. Invest New Drugs. 2013. PMID: 23315029 Clinical Trial.
21 results
Jump to page